Forschungspreise

Prim. Univ. Doz. Dr. Peter Lind
1985: Forschungspreis der wiss. Gesellschaft der Ärzte in der Steiermark
1996: Forschungspreis der Österreichischen Krebshilfe

EOA Univ. Doz. Dr. HJ Gallowitsch
1995: Mallinckrodt- Forschungspreis der Österreichischen Gesellschaft für Nuklearmedizin
1996: Förderungspreis der med. wiss. Gesellschaft für Kärnten
1998: Förderungspreis der med. wiss. Gesellschaft für Kärnten
 
OA Univ. Doz. Dr. P Mikosch
1997: Förderungspreis der med. wiss. Gesellschaft für Kärnten
1999: österr. Biochemie Forschungspreis für Schilddrüsenerkrankungen
2000: österr. Biochemie Forschungspreis für Schilddrüsenerkrankungen


OÄ Dr. I Igerc
2009: Mallinckrodt- Forschungspreis der Österreichischen Gesellschaft für Nuklearmedizin

Habilitationen (Verleihung der Lehrbefugnis als Universitätsdozent)

Innerhalb der Abteilung wurde die Lehrbefugnis als Universitätsdozent verliehen an:

2000: Univ.-Doz. Dr. Hans-Jürgen Gallowitsch
2003: Univ.-Doz. Dr. Peter Mikosch
2004: Univ.-Doz. Dr. Ewald Kresnik

2008: Verleihung des Titels „Universitätsprofessor“ an Prof. Dr. Peter Lind

Publikationen

Originalarbeiten

1.  Kohlfürst S, Igerc I, Lobnig M, Gallowitsch HJ, Gomez I, Matschnig S, Mayr J, Mikosch P, Beheshti Mohsen, Lind P. I 131 posttherapeutic SPECT-CT offers a high diagnostic accuracy  in case of inconclusive findings in conventional planar imaging and allows a tailored patient treatment regimen. Eur J Nucl Med Mol I: 2009 Jun;36(6):886-93
2.  Beheshti M, Pöcher S, Vali R, Waldenberger P, Broinger G, Nader M, Kohlfürst S, Pirich C, Dralle H, Langsteger W. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur Radiol.2009 Jun;19(6):1425-34.
3.  Luster M, Pediatric rhTSH Investigators group. Recombinant thyrotropin use in children and adolescents with differentiated thyroid cancer: a multicenter retrospective study. J Clin Endocrinol Metab.2009 Oct;94(10):3948-53.
4.  Kohlfürst S, Markitz M, Raunik W, Eckel  HE, Kresnik E, Hausegger K, Salzwimmer M, Gaggl A, Chiari F, Lind P. Diagnostik, Therapieplanung und Nachsorge von Kopf-Hals- Karzinomen Überlegungen einer interdisziplinären Konsensus- Konferenz. Laryngo Rhino Otol 2009 Feb;88(2):84-90
5.  Igerc I, Kohlfürst S, Gallowitsch HJ, Matschnig S, Kresnik E, Gomez-Segovia I, Lind P. The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer. Eur J Nucl Med Mol Imaging. 2008 May;35(5):976-83.
6.  Mikosch P, Kerschan-Schindl K, Woloszczuk W, Stettner H, Kudlacek S, Kresnik E, Gallowitsch HJ, Lind P, Pietschmann P. High cathepsin K levels in men with differentiated thyroid cancer on suppressive L-thyroxine therapy. Thyroid 2008 Jan;18(1):27-33.
7.  Gallowitsch HJ, Kraschl P, Igerc I, Hussein T, Kresnik E, Mikosch P, Kohlfuerst S. Hausegger K, Lind P. Sentinel node SPECT-CT in breast cancer. Can we expect any additional and clinically relevant information? Nuklearmedizin. 2007;46(6):252-6.
8.  Kohlfürst S, Igerc I, Gallowitsch HJ, Gomez I, Kresnik E,Matschnig S, Lind P. Is there a role for sandostatin in patients with progressive thyroid cancer and iodine-negative but somastotatin-receptor positive metastases? Thyroid. 2006 Nov;16(11):1113-9.
9.  Zoller M, Kohlfürst S, Igerc I, Kresnik E, Gallowitsch HJ, Gomez I, Lind P. Combined PET/CT in the follow- up  of differentiated thyroid carcinoma: what is the impact of each modality? Eur J Nucl Med Mol Imaging. 2006 Nov 14;
10.  Lind P, Kohlfürst S. Respective roles of thyroglobulin, rdioiodine imaging and positron emission tomography in the assessment of thyroic cancer. Sem in Nucl Med. 2006 Jul; 36(3):194-205.
11.  Mikosch P, Igerc I, Kudlacek S, Wolosczczuk W, Gallowitsch HJ, Kresnik E, Stettner H, Grimm G, Lind P, Pietschmann P. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin in men with thyreoid cancer. Eur J Clin Invest.2006 Aug;36(8):566-73
12.  Lind P, Igerc I, Kohlfürst S. Diagnosis, treatment and follow-up in the case of differentiated thyroid cancer Wien Med Wochenschr 2005 Oct;155(19-20):429-35.   
13.  Gallowitsch HJ (2005). Thyroid and cardiovascular system. Wien Med Wochenschr  155/19-20: 436-443
14.  Pacini F, Schlumberger M, Harmer C, Berg GG, Cohen O, Duntas L,  Jamar F, Jarzab B, Limbert E, Lind P, Reiners C, Sanchez Franco F, Smit J, Wiersinga W.  Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer  an the issue of remnant ablation: a consensus report.  Eur J Endocrinol 2005 Nov;153(5):651-9.

15.  Hausegger K, Reinprecht P, Kau T, Igerc I, Lind P. Clinical experience with a commercially available negative oral contrast  medium in PET/CT. Rofo 2005 Jun; 177(6):796-9.
16.  Kohlfürst S, Igerc I, Lind P. Recombinanat human thyrotropin is helpful in the fllow-up and 131I-therapy  of patients with thyroid cancer: a report of the results and benefits using recombinant human thyrotropin in clinical routine. Thyroid 2005 Apr; 15(4):371-376.
17.  Schlumberger M, Pacini F, Wiersinga WM, Toft A, Smit JW, Sanchez Franco F, Lind P, Limbert E, Jarzab B, Jamar F, Duntas L, Cohen O, Berg G. Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice. Eur J Endocrinol 2004 Nov; 151(5):539-48.
18.  Gomez Segovia I, Gallowitsch HJ, Kresnik E, Kumnig G, Igerc I, Matschnig S, Stronegger WJ, Lind P. Descriptive epidemiology of thyroid cancinoma in Carinthia, Austria: 1984-2001. Histopathologic features and tumor classification of 734 cases under elevated general iodination of table salt since 1990:population-based age-stratified analysis  on thyroid carcinoma incidence. Thyroid 2004 Apr; 14(4):277-86.
19.  Lind P, Igerc I , Beyer T, einprecht P, Hausegger K. Advantages and limitations of FDG PET in the follow-up of breast cancer. Eur J Nucl Med Mol Imaging 2004 Jun; 31 Suppl 1:S125-34 Epup 2004 Apr 15.
20.  Schlumberger M, Berg G, Cohen O, Duntas L,  Jamar F,Jarzab B, Limbert E, Lind P, Pacini F, Reiners C, Sanchez Franco F, Toft A, Wiersinga WM. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004 Feb; 150(2):105-12.
21.  Heinisch M, Gallowitsch HJ, Mikoch P, Kresnik E, Kumnig G, Gomez I, Lind P, Umschaden HW, Gasser J, Forsthuber EP. Comparison of FDG-PET and dynamic contrast-enhanced MRI in the evaluation of suggestive breast lesions. Breast 2003 Feb; 12(1):17-22.
22.  Kohlfürst S, Igerc I, Lind P. FDG PET  helpful for diagnosing SAPHO syndrome. Clin Nucl Med. 2003 Oct;28(10)838-9
23.  Mikosch P, Obermayer-Pietsch B, Jost R, Jauk B, Gallowitsch HJ, Kresnik E, Leb G, Lind P. Bone metabolism in patients with differentiated thyroid carcinoma receiving suppressive levothyroxine treatment. Thyroid 2003 Apr;13(4):347-56.
24.  Mikosch P, Gallowtisch HJ, Zinke-Cerwenka W, Heinisch M, Pipam W, Eibl M, Kresnik E, Unterweger O, Linkesch W, Lind P. Accuracy of whole-body 18F-FDG-PET for restaging malignant lymphoma. Acta Med Austriaca 2003;30(2)41-7.
25.  Gallowitsch HJ, Kresnik E, Gasser J, Kumnig G, Igerc I, Mikosch P, Lind P. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastses in the follow up of patients with breast carcinoma: a comparison to conventional imaging. Inves Radiol. 2003 May, 38(5):250-6.
26.  Kresnik E, Gallowitsch HJ, Mikosch P, Stettner H, Igerc I, Gomez I, Kumnig G, Lind P. Fluorine-18-fluorodeoxyglucose positron emission tomography in the preoperative assessment of thyroid nodules in an endemic goiter area.
27.  Mikosch P, Würtz FG, Gallowitsch HJ, Kresnik E, Lind P. F-18-FDG-PET in a patient with Hashimoto’s thyreoiditis  and MALT lymphoma recurrence of the thyroid.

28.  Mikosch P, Jauk B , Kaulfersch W, Gallowitsch HJ, Lind P. Scintigraphic findings in a patient with sickle-cell thalassemia and recurrent pain attacks. Wien Med Wochenschr.2003;153(3-4):83-8.
29.  Lind P. Should high hTg levels in the absence of iodine uptake be treated? Eur J Nucl Med Mol Imaging 2003 Jän;30(01):157-60
30.  Lind P, Kresnik E, Kumnig G, Gallowitsch HJ, Igerc I,  Matschnig S, Gomez I. 18F-FDG-PETin the follow-up of thyroid cancer. Acta Med Austriaca 2003;30(1):17-21.
31.  Ramschak-Schwarzer S, Langmann A, L indner S, Pretterhofer U,  Moncayo R, Baldissera I, Lind P, Ettl A, Maschek W, Pichler R, Weissel M, Leb G. Diagnosis and therapy on Graves’ ophthalmopathy—consensus guidelines. Acta Med. Austriaca 2002;29(4):117-9.
32.  Gallowitsch HJ, Konstantiniuk P, Jörg L, Urbania A, Kugler F, Peschina W, Hatzl-Griesenhofer M, Zettinig P (2002) Identification of sentinel lymph nodes in breast cancer by lymphoscintigraphy and gamma probe guidance: Dependence on route of injection and tumour location. Eur Surg; 34, 267-71
33.  Heinisch M, Kumnig G, Asbock D, Mikosch P, GallowitschHJ, Kresnik E, Gomez I, Unterweger O, Lind P. Goiter  prevalence and urinary iodide excretionin a formerly iodine-deficient region after introduction of statutory iodization of common salt. Thyroid 2002 Sept; 12(9):809-14.
34.  Sinzig M, Lesnik G, Gomez I, Haselbach H. Urogenitale Akutsituationen. Radiologe 2002; 42:171-178.
35.  Lind P. Stategies for radioiodine therapy for Graves disease. Eur J Nucl Med 2002, 29: S453-S457
36.  Lind P, Kumnig G, Heinisch M, Mikosch P, Gallowitsch HJ, Kresnik E, Gomez I, Unterweger O, Aigner H. Iodine supplementation in Austria: Methods and results. Thyroid 2002 ; 12: 903-907
37.  Kresnik E, Gallowitsch HJ, Mikosch P, Alberer D, Würtz F, Hebenstreit A, Kogler D, Gasser J, Kumnig G, Gomez I, Lind P. F-18-FDG PET in the early diagnosis of enterocolitis: preliminary results. Eur J Nucl Med 2002  29: 1389-1392
38.  Heinisch M, Kumnig G, Asböck d, Mikosch P, Gallowitsch HJ, Kresnik E, gomez I, Unterweger O, Lind P. Goiter prevanlence and urinary iodine excretion in a formerly iodine-deficient regionafter introduction of satutory iodization of common salt. Thyroid 2002; 12: 809-814
39.  Kresnik E, Mikosch P, Gallowitsch HJ, Jesenko R, Just H, Kogler D, Heinisch M, Unterweger O, Kumnig G, Gomez I, Lind P. Clinical outcome of radiosynoviorthesis. A meta-analysis including 2190 treated joints. Nucl Med Commun 2002; 23: 683-688
40.  Kresnik E. F-18-FDG PET in der Abklärung von Tumoren im HNO Bereich : Literaturübersicht und eigene Ergebnisse. Wien Med  Wschr 2002, 152: 255-258
41.  Mikosch P. F-18-FDG PET bei malignen Lymphomen. Wien Med  Wschr 2002, 152: 269-275
42.  Kumnig G. Stellenwert der F-18-FDG PET beim Schilddrüsenkarzinom. Wien Med  Wschr 2002, 1280-285
43.  Igerc I, Kumnig G, Heinisch M, Kresnik E, Mikosch P, Gallowitsch HJ, Gasser J, Haselbach H, Lind P. vocal cord muscle activity as a drawback to FDG PET in the follow up of differentiated thyroid cancer. Thyroid 2002; 12: 87-89
44.  Gallowitsch HJ, Heinisch M, Mikosch P, Kresnik E, Kumnig G, Gomez I, Lind P. Tc-99m Ciprofloxacin in clinically selected patients suspected for peipheral osteomyelitis, spondylodiscitis and fever of unknown origin. NuclearMedicine 2002; 41: 30-36
45.   Mikosch P, Wartner U, Kresnik E, Gallowitsch HJ, Heinisch M, Dinges HP, Lind P. Results of preoperative ultrasound guided fine needle aspiration biops of solitary thyroid nodules as compared with the histology. Nuclear Medicine 2002; 41: 148-154
46.  A. Weinhäusl, Gomez-Segovia I, Behmel A,  Lind P,  Haas O. Identifikation of a Novel PRKA R1A-Mutation Predisposing for Corney Complex Disease. The Journal of Endocrine Geneties, 2002; 3:33-36.
47.  Kresnik E, Mikosch P, Gallowitsch HJ, Heinisch M, Lind P. F-18-FDG PET in the diagnosis of inflammatory bowel disease. Clin Nucl Med 2001; 26; 867

48.  Lind P. Ablative therapy for immune hyperthyroidism in patients with ophthalmopathy. AMA 2001; 28: 105-107
49.  Kresnik E, Mikosch P, Gallowitsch HJ, Kogler D, Wieser S, Heinisch M, Unterweger O, Raunik W, Kumnig G, Gomez I, Grünbacher G, Lind P. Evaluation of head and neck cancer with F-18-FDG PET: a comparison with conventional methods. Eur J Nucl Med 2001: 28: 816-821
50.  Mikosch P, Pietschmann P, Kainberger F, Gallowitsch HJ, Lind P. Pagets disease or fibrous dysplasia of the radius: a case report. Wien Med  Wschr 2001, 151: 295-299
51.  Gomez-Segovia I, Gallowitsch HJ, Kresnik E, Kumnig G, MikoschP  and Lind P. Cushing’s Syndrome Caused by Primary Pigmented Adrenocortical Micronodular Dysplasia – A Familial lose. The Journal of Endocrine Genetics 2, 2001;1:69-176.
52.  Crone I, Pfäffle F, Stoble H, Prayer D, Gomez I, Fisch F. Familial  Combined Pituitary Hormon Deficiancy caused by PROP-1 Gene Mutation. Growth Patterns and MRI Studies in untreated subjects. Horm.Res.2002, 57:120-126
53.  Mikosch P, Gallowitsch HJ, Kresnik e Lind P. Präoperative Dignitätsbeurteilung von Schilddrüsenknoten im Strumaendemiegebiet: Möglichkeiten und Limitationen. Wien Med Wschr 2001;150: 278-287
54.  Mikosch P, Jauk B, Gallowitsch HJ, Pipam W, Kresnik E, Lind P. Suppressive L-Thyroxine Therapy has no significant Infliuence on Bone Degradation inWomen with Thyroid Carcinoma. A Comparison with other Disorders Affecting Bone Metabolism. Thyroid 2001; 11: 257-263
55.  Lind P,  Kumnig G, Matschnig S,  Heinisch M, Gallowitsch HJ, Mikosch P, Kresnik E, Gomez I. Unterweger O. The role of F-18-FDG PET in thyroid cancer. AMA 2000; 27: 38-41
56.  Lechner P, Lind P, Goldenberg DM. Can postoperative surveillance with serial CEA immunoscintigraphy detect resectable rectal cancer recurrence and potentially improve tumor-free survival. Am Coll  Surg 2000;191511-518
57.  Mikosch P, Gallowitsch HJ, Kresnik E, Jester J, Würtz FG, Kerschbaumer K, Unterweger O, Dinges HP, Lind P. Value of ultrasound-guided fine needle aspiration biopsy of thyroid nodules in an endemic goitre area. Eur J Nucl Med 2000;27:62-69
58.  Gallowitsch HJ, Mikosch P, Kresnik E, Unterweger O, Lind P. Comparison between Tc-99m-tetrofosmin/pertechnetate subtraction scintigraphy and Tc-99m tetrofosmin SPECT for preoperative localisation of parathyroid adenoma in an endemic goiter area. Invest Radiol 2000; 35: 453-459
59.  echner P, Lind P, Snyder M, Haushofer H. Probe-guided surgery for colorectal cancer. Recent Results Cancer Res 2000; 157: 273-280
60.  Kresnik E, Gallowitsch HJ, Mikosch P, Unterweger O, Gomez I, Lind P. Scintigraphic and ultrasonographic appearance in different tumor stages of thyroid carcinoma. AMA  2000;27:32-35
61.  Anhaus S, Niederwieser G, Bonelli RM, Lind P, Reissecker F, Költringer P. Speech disturbances and dyskinesias as initial symptoms of cortico-basal degeneration. Nervenarzt 2000; 71: 311-315
62.  Mikosch P, Gallowitsch HJ, Kresnik E, Lind P. Osteoporose bei Turner Syndrom mit gonosomalem Mosaik (45,X0/46,XY) - Ein Fallbericht. Wien Med Wschr 2000; 150:262-265
63.  Lind P. I-131 whole body scintigraphy in thyroid cancer patients. Q J Nucl Med 1999; 43: 188-194
64.  Lind P, Gallowitsch HJ, Mikosch P, Kresnik E, Gomez I, Kumnig G, Matschnig S, Unterweger O, Dinges HP. Comparison of different tracers in the follow up of differentiated thyroid carcinoma. AMA 1999; 26: 115-118
65.  Lind P.  Multi-tracer imaging of thyroid nodules: is there a role in the preoperative assessment of nodular goiter ? Eur J Nucl Med 1999; 26: 795-797
66.  Mikosch P, Gallowitsch HJ, Kresnik E, Lind P. Schilddrüsenhemiagenesie mit Immunthyreopathie. Nuklearmedizin 1999; 38:35-37
67.  Jauk B, Mikosch P, Gallowitsch HJ, Kresnik E, Molnar M, Gomez I, Lind P. Unusual malabsorbtion of levothyroxine. Thyroid 2000; 10: 93-95

68.  Gallowitsch HJ, Unterweger O, Mikosch P, Kresnik E, Sykora J, Grimm G, Lind P.  Attenuation-correction improves the detection of viable myocardium by Tl-201 cardiac tomography in patients with previous myocardial infarction and left ventricular  dysfunction. Eur J Nucl Med 1999; 26:459-466
69.  Mikosch P, Gallowitsch HJ, Kresnik E, Unterweger O, Gomez I, Lind P. Comparison of Two Thyroglobulin Immunoradiometric Assays on the Basis of Comprehensive Imaging in Differentiated Thyroid Carcinoma. Thyroid 1999; 9:933-941
70.  Mikosch P, Gallowitsch HJ, Kresnik E, Molnar M, Gomez I, Lind P. Thyroid hemiagenesis in an endemic goiter area diagnosed by ultrasonography: report of sixteen patients. Thyroid 1999; 9:1075-1083
71.  Kresnik E, Gallowitsch HJ, Mikosch P, Molnar M, Unterweger O, Gomez I, Lind P. Immunoscintigraphy of an inflammatory process in Crohn’s disease with a Tc-99m labeled fragment (MN3Fab’) and with an intact monoclonal anti-granulocyte antibody (Mab BW 250/183) Clin Nucl Med 1999;24:64-65
72.   Gallowitsch HJ, Mikosch P, Kresnik E, Starlinger M, Lind P. Lymphoscintigraphy and gamma-probe guided surgery in papillary thyroid carcinoma. The sentinel lymph node concept in thyroid carcinoma. Clin Nucl Med 1999; 10: 744-746
73.  Gallowitsch HJ, Mikosch P, Kresnik E, Unterweger O, Gomez I, Lind P. Thyroglobulin, low dose I-131 and Tc-99m tetrofosmin WBS: A direct comparison under endogenous TSH-stimulation. J Nucl Med 1998; 39:870-875
74.  Gallowitsch HJ, Sykora J, Mikosch P, Kresnik E, Unterweger O, Molnar M, Grimm G, Lind P. Attenuation-corrected Tl-201 - SPECT using a Gd-153 moving line source: Clinical value and the impact of attenuation correction on the extent and severity of  perfusion abnormalities. Eur J Nucl Med 1998; 25:220-228
75.  Mostbeck A, Galvan G, Bauer P, Eber O, Atefie K, Dam K, Feichtinger H, Fritzsche H, Haydl H, Köhn H, König B, Koriska K, Kroiss A, Lind P, Markt B, Maschek W, Pesl H, Ramschak-Schwarzer S, Riccabona G,   Stockhammer M, Zechmann W. The incidence of  hyperthyreoidism in Austria from 1987 to 1995 before and after an increase in salt iodization in 1990. Eur J Nucl Med. 1998; 25: 367-74
76.  Ruhlmann J, Oehr P, Bender H, Kozak B, Willkomm P, Bechtold V, Lind P, Biersack HJ. Toxicity and radiation dosage of 2-(18F)-2-deoxy-D-glucose in positron emission  tomography. AMA 1998; 25: 1-6
77.  Gallowitsch HJ, Fellinger J, Kresnik E, Mikosch P, Lind P.  Scintigraphic and intraoperative scintimetric localization of an Ectopic parathyroid adenoma with Tc-99m Tetrofosmin and Tc-99m Sestamibi.  Acta Chir. Austriaca 1998; 30:119-25
78.  Lind P, Kesnar S, Gallowitsch HJ, Unterweger O, Mikosch P, Gillhofer G, Henning K. F-18 Deoxyglucose PET bei malignen Keimzelltumoren. J Urol Urogynäkol 1998; Sonderheft 1:5-8
79.  Lind P, Langsteger W, Molnar M, Gallowitsch HJ, Mikosch P, Gomez I. Epidemiology of thyroid diseases in iodine sufficiency. Thyroid 1998, 8: 1179-1183
80.  Lind P, Umschaden HW, Forsthuber E, Oman J, Kerschbaumer K, Gallowitsch HJ, Mikosch P, Kresnik E, Gomez I. Scintimammography using Tc-99m Tetrofosmin. AMA  1997; 24: 50-54
81.  Lind P. Parathyroid imaging with Tc-99m labelled cationic complexes: which tracer and which technique should be used ?  Eur J Nucl Med 1997; 24: 243-245
82.  Lind P, Gallowitsch HJ, Langsteger W, Kresnik E, Mikosch P, Gomez I. Tc-99m tetrofosmin whole body scintigraphy in the follow up of differentiated thyroid carcinoma. J Nucl Med 1997; 38: 348-352
83.  Lind P, Gallowitsch HJ, Kresnik E, Gomez I, Oman J, Dinges, Boniface G. Radioimmuniscintigraphy with Tc-99m  labeled monoclonal antibody 170 H.82 in patients with suspected primary, recurrent or metastatic breast cancer.  Clin Nucl Med 1997; 22: 30-34
84.   Gallowitsch HJ, Fellinger J, Mikosch P, Kresnik E, Lind P. Gamma probe-guided resection of a lymph node metastasis with Iodine-123 in papillary thyroid carcinoma. Clin Nucl Med 1997; 22; 591-592
85.  Kresnik E, Gallowitsch HJ, Mikosch P, Gomez I, Lind P. Tc-99m MIBI scintigraphy of thyroid nodules in an endemic goiter area. J Nucl Med 1997;38:62-65
86.   Kresnik E, Gallowitsch HJ, Mikosch P, Lind P. MIBI and thyroid tumors. J Nucl Med 1997;38:1501
87.  Kresnik E, Gallowitsch HJ, Mikosch P, Molnar M, Lind P. Tetrofosmin scintigraphy of thyroid disease. Eur J Nuc Med 1997; 24:1332

88.  Gallowitsch HJ, Fellinger J, Kresnik E, Mikosch P, Pipam W, Lind P. Preoperative scintigraphic and intraoperative scintimetric localization of parathyroid adenoma with cationic Tc-99m complexes and a hand held gamma-probe. NuclearMedicine 1997;36:13-16
89.  Tschabitscher D, Gallowitsch HJ, Mikosch P, Kresnik E, Molnar M, Dinges HP, Kroiss A, Lind P. Tc-99m Tetrofosmin uptake in sarcoidosis stage I.  J Nucl Med 1997; 38: 1786-1787
90.  Harder W, Lind P,  Mollnar M, Mikosch P, Gomez I, Gallowitsch HJ, Kresnik E, Dinges HP. Thallium -201 Uptake with Negative I-131 Scintigraphy and Serum Thyroglobulin in Metastatic Oxiphilic Papillary Thyroid Carcinoma. J Nucl Med 1997; 39: 236-238
91.  Mikosch P, Gallowitsch HJ, Kresnik E, Lind P. Schwannoma of the Neck Simulating a Thyroid Nodule. Thyroid 1997, 7: 449-451
92.  Kresnik E, Gallowitsch HJ, Mikosch P, Molnar M, Pipam W, Gomez I, Lind P. Evaluation of thyroid nodules with Tc-99m tetrofosmin dual phase scintigraphy. Eur J Nucl Med 1997; 24: 716-721
93.  Mikosch P, Gallowitsch HJ, Kresnik E, Lind P. Achalasia Diagnosed by Tc-99m Pertechnetate  Scintigraphy. NuclearMedicine 1997, 36:142-145
94.   Mikosch P, Gallowitsch HJ, Kresnik E, Molnar M, Gomez I, Lind P. Influence of human anti-mouse antibodies on thyrotropin in-vitro analysis: a comparison of  6 thyrotropin IRMA kits. European Journal of Clinical Chemistry and Clinical Biochemistry 1997; 35:881-883
95.  Gallowitsch HJ, Mikosch P, Kresnik E, Unterweger O, Lind P. Tc-99m tetrofosmin parathyroid imaging: Results with double phase study and SPECT in primary and
96.  secondary hyperparathyroidism. Invest Radiol 1997; 32: 459-465
97.  Gallowitsch HJ, Fellinger J, Kresnik E, Mikosch P, Pipam W, Unterweger O, Lind P. The use of gamma probe for intraoperative localization of parathyroid adenomas with Tc-99m tetrofosmin and Tc-99m sestamibi. AMA 1997; 24: 73-78
98.  Lind P, Gallowitsch HJ, Kogler D, Kresnik E, Mikosch P, Gomez I. Tc-99m tetrofosmin scintimammography: a prospective study in primary breast lesions. NuclearMedicine ; 1996; 35: 225-229
99.  Lind P, Gallowitsch HJ. The use of non-specific tracers in the follow up of differentiated thyroid cancer: Results with Tc-99m tetrofosmin whole body scintigraphy. AMA 1996; 23: 69-75
100.  Gallowitsch HJ, Kresnik E, Mikosch P, Pipam W, Gomez I, Lind P. Tc-99m Tetrofosmin scintigraphy : An alternative method for following up differentiated thyroid carcinoma - preliminary results . NuclearMedicine 1996;35:230-235
101.  Lechner P, Lind P, Binter G. Tc-99m markierte anti-CEA Antikörper in der intraoperativen Diagnostik kolorektaler Karzinome. Nuklearmedizin 1995;34:8-14
102.  Kresnik E, Gallowitsch HJ, Plöb J, Gomez I, Mikosch P, Dinges HP, Lind P.    Squamous cell carcinoma of the thyroid originating from a thyroglossal ductal cyst NuclearMedicine 1995;34:104-109.
103.  Mikosch P, Gallowitsch HJ, Gomez I, Kresnik E, Plöb J, Lind P. Diagnostik der SDAT mittels HMPAO-SPECT und Serumvitamin-B12 Spiegel. Nuklearmedizin 1995;34:104-109
104.   Gallowitsch HJ, Mikosch P, Kresnik E, Gomez I, Plöb J, Pipam W, Lind P. Schilddrüsenvolumina und Jodversorgung 6-19 jähriger Schüler. Nuklearmedizin 1994;33:235-238
105.  Köhn H, Mostbeck A, Bachmayr S, Eber O, Galvan G, Holm Ch, König B, Lind P, Markt B, Ogris E, Rettenbacher L. Tc-99m DTPA aerosol for same-day post perfusion ventilation imaging. Results of a multicentre study. Eur J Nucl Med 1993;20:4-9
106.  Czermak, Gomez I, Gallowitsch HJ, Lind P. Stellenwert nuklearmedizinischer Methoden in der Differentialdiagnose solider Leberherde. Nuklearmedizin 1993;32:183-187
107.  Lechner P, Lind P, Binter G, Cesnik H. Anticarcinoembryonic antigen immunoscintigraphy with a Tc-99m Fab´ fragment (IMMU-4) in primary and recurrent colorectal cancer. Dis Colon Rectum 1993;36:930-935
108.  Reisecker F, Költringer P, Lind P, Leblhuber F, Eber O. Lack of specificity of single photon emission computerized tomography in dementia: Results of a case of progressive paralysis. Nervenarzt 1992; 63: 371-374
109.  Langsteger W, Költringer P, Lind P, Pierer G, Reisecker F, Eber O. The effect of rapid hypervolemic hemodilution on blood viscoelasticity:  course observation over 5 days. Clin Hemorheol 12(Suppl 1)1992:93-100
110.  Eber O, Langsteger W, Lind P, Schubert B, Stradner F. Endokrine Regulationsstörungen bei Adipositas. Therapiewoche Österreich 1992;1:19-25
111.  Buchinger W, Eber O, Uray G, Lind P, Lindner W. Synthesis and effects on peripheral thyroid hormone conversion of (R)-4-Hydroxypropranolol, a main metabolite of ( R )- Propranolol. Chirality 1991;3:145-150
112.  Schwarzer S, Eber B, Greinix H, Lind P. Non-Q- wave myocardial infarction associated with bleomycin and etoposide chemotherapy. Eur Heart J 1991,12:748-7
113.  Lind P, Lechner P, Arian-Schad K, Klimpfinger M, Langsteger W, Költringer P, Kronberger L Cesnik H, Kammerhuber F, Eber O. Anti CEA immunoscintigraphy (Tc-99m MAb BW 431/26) and serum CEA levels in patients with suspected primary and recurrent colorectal carcinoma. J Nucl Med 1991;32: 1319-1325
114.  Lind P, Smola MG, Lechner P, Ratschek M, Klima G, Költringer P, Steindorfer P, Eber O. The immunoscintigraphic use of Tc-99m-labelled monoclonal anti-CEA antibodies (BW431/26) in patients with suspected primary, recurrent and metastatic breast cancer. Int J Cancer 1991; 47:865-9

>>zum Anfang